List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
29 July 2025 | By Eurofins Discovery
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
UBC Okanagan researchers have developed a new 3D bio-printed lung model that closely mimics the complexity of human tissue – providing scientists with a powerful new tool for studying respiratory diseases.
Scientists have found a key mechanism driving immune regulation in autoimmune diseases like MS and IBD – which could lead to new targeted treatments.
In the fight against antibiotic-resistant bacteria, researchers at Michigan State University (MSU) have made a discovery that could change how we target deadly pathogens like Staphylococcus aureus and its drug-resistant strain - MRSA.
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
A new international framework introduces rigorous validity standards for the use of brain organoids and iPSC-derived models in studying neuropsychiatric disorders. These guidelines aim to accelerate drug discovery and bring precision treatments closer to reality.
A new stroke treatment, GAI-17, developed by researchers in Japan, has shown encouraging results in reducing brain cell death and paralysis in animal models – potentially allowing for future development of treatments for other brain disorders.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
A new dual CAR-T cell therapy targeting two tumour-specific proteins in T-cell Acute Lymphoblastic Leukaemia (T-ALL) has been developed – meaning effective treatment for this aggressive blood cancer could soon become a reality.
Researchers in Japan have developed long-lasting 3D liver organoids from stem cells by incorporating bile acids into the culture medium - offering a new model for studying chronic liver diseases.
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
